September 4, 2020

Laura Clague Chief Financial Officer Retrophin, Inc. 3721 Valley Centre Drive, Suite 200 San Diego, CA 92130

> Re: Retrophin, Inc. Form 10-K for the

Fiscal Year Ended December 31, 2019

Filed February 24,

2020

File No. 001-36257

Dear Ms. Clague:

 $\label{eq:weak_equation} \mbox{We have limited our review of your filing to the financial statements and related}$

disclosures and have the following comments. In some of our comments, we may ask you to

provide us with information so we may better understand your disclosure.

 $\hbox{ Please respond to these comments within ten business days by providing the requested } \\$

information or advise us as soon as possible when you will respond. If you do not believe our

comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Form 10-K for the Fiscal Year Ended December 31, 2019

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Results of Operations - Operating Expenses, page 53

1. We note your selling, general and administrative expenses increased by 24% due to increased legal and compensation expenses. In future filings, please describe in further detail the underlying reasons for the significant increase and provide additional quantitative

information as necessary.

Consolidated Financial Statements Note 9. Intangible Assets Thiola License Agreement, page F-22

2. We note that in 2019 you added \$15.8 million to intangible assets related to royalties in excess of the minimum. Please explain to us the basis for your accounting treatment to

Please explain to us the basis for your accounting treatment Laura Clague

Retrophin, Inc.

September 4, 2020

Page 2

capitalize royalty payments in excess of minimum royalties and the accounting literature $% \left(1\right) =\left(1\right) \left(1\right) +\left(1\right) \left(1\right) \left(1\right) +\left(1\right) \left(1$

that you relied on for this treatment. Please explain to us the reason you do not expense $\,$

the annual royalty payments.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review,

comments, action or absence of action by the staff.

You may contact Michael Fay at 202-551-3812 or Brian Cascio, Accounting Branch

Chief, at 202-551-3676 with any questions.

FirstName LastNameLaura Clague Comapany NameRetrophin, Inc.

Corporation Finance September 4, 2020 Page 2 Sciences FirstName LastName Sincerely,
Division of
Office of Life